Cargando…

Adiponectin and Lipoprotein Particle Size

OBJECTIVE: Adiponectin has been postulated to affect lipid and insulin signal transduction pathways. We evaluated the relationships of plasma adiponectin with lipoprotein mean particle size and subclass concentrations, independent of obesity and insulin sensitivity. RESEARCH DESIGN AND METHODS: A cr...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiss, Ram, Otvos, James D., Flyvbjerg, Allan, Miserez, Andre R., Frystyk, Jan, Sinnreich, Ronit, Kark, Jeremy D.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699707/
https://www.ncbi.nlm.nih.gov/pubmed/19389813
http://dx.doi.org/10.2337/dc09-0084
_version_ 1782168521021587456
author Weiss, Ram
Otvos, James D.
Flyvbjerg, Allan
Miserez, Andre R.
Frystyk, Jan
Sinnreich, Ronit
Kark, Jeremy D.
author_facet Weiss, Ram
Otvos, James D.
Flyvbjerg, Allan
Miserez, Andre R.
Frystyk, Jan
Sinnreich, Ronit
Kark, Jeremy D.
author_sort Weiss, Ram
collection PubMed
description OBJECTIVE: Adiponectin has been postulated to affect lipid and insulin signal transduction pathways. We evaluated the relationships of plasma adiponectin with lipoprotein mean particle size and subclass concentrations, independent of obesity and insulin sensitivity. RESEARCH DESIGN AND METHODS: A cross-sectional analysis of 884 young Israeli adults who participated in the population-based Jerusalem Lipid Research Clinic (LRC) study was conducted. Lipoprotein particle size was assessed using proton nuclear magnetic resonance. RESULTS: In multivariable linear regression models that included sex, BMI, waist circumference, homeostasis model assessment of insulin resistance, and leptin, adiponectin was associated with mean LDL size (standardized regression coefficient B = 0.20; P < 0.001), VLDL size (B = −0.12; P < 0.001), and HDL size (B = 0.06; P = 0.013). Adiponectin was inversely related to large VLDL (P < 0.001) but positively to small VLDL (P = 0.02), inversely related to small LDL (P < 0.006) but positively to large LDL (P < 0.001), and positively related to large HDL (P < 0.001) subclass concentrations. CONCLUSIONS: Adiponectin is favorably associated with lipoprotein particle size and subclass distribution independent of adiposity and insulin sensitivity.
format Text
id pubmed-2699707
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-26997072010-07-01 Adiponectin and Lipoprotein Particle Size Weiss, Ram Otvos, James D. Flyvbjerg, Allan Miserez, Andre R. Frystyk, Jan Sinnreich, Ronit Kark, Jeremy D. Diabetes Care Original Research OBJECTIVE: Adiponectin has been postulated to affect lipid and insulin signal transduction pathways. We evaluated the relationships of plasma adiponectin with lipoprotein mean particle size and subclass concentrations, independent of obesity and insulin sensitivity. RESEARCH DESIGN AND METHODS: A cross-sectional analysis of 884 young Israeli adults who participated in the population-based Jerusalem Lipid Research Clinic (LRC) study was conducted. Lipoprotein particle size was assessed using proton nuclear magnetic resonance. RESULTS: In multivariable linear regression models that included sex, BMI, waist circumference, homeostasis model assessment of insulin resistance, and leptin, adiponectin was associated with mean LDL size (standardized regression coefficient B = 0.20; P < 0.001), VLDL size (B = −0.12; P < 0.001), and HDL size (B = 0.06; P = 0.013). Adiponectin was inversely related to large VLDL (P < 0.001) but positively to small VLDL (P = 0.02), inversely related to small LDL (P < 0.006) but positively to large LDL (P < 0.001), and positively related to large HDL (P < 0.001) subclass concentrations. CONCLUSIONS: Adiponectin is favorably associated with lipoprotein particle size and subclass distribution independent of adiposity and insulin sensitivity. American Diabetes Association 2009-07 2009-04-23 /pmc/articles/PMC2699707/ /pubmed/19389813 http://dx.doi.org/10.2337/dc09-0084 Text en © 2009 by the American Diabetes Association. https://creativecommons.org/licenses/by-nc-nd/3.0/Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ (https://creativecommons.org/licenses/by-nc-nd/3.0/) for details.
spellingShingle Original Research
Weiss, Ram
Otvos, James D.
Flyvbjerg, Allan
Miserez, Andre R.
Frystyk, Jan
Sinnreich, Ronit
Kark, Jeremy D.
Adiponectin and Lipoprotein Particle Size
title Adiponectin and Lipoprotein Particle Size
title_full Adiponectin and Lipoprotein Particle Size
title_fullStr Adiponectin and Lipoprotein Particle Size
title_full_unstemmed Adiponectin and Lipoprotein Particle Size
title_short Adiponectin and Lipoprotein Particle Size
title_sort adiponectin and lipoprotein particle size
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699707/
https://www.ncbi.nlm.nih.gov/pubmed/19389813
http://dx.doi.org/10.2337/dc09-0084
work_keys_str_mv AT weissram adiponectinandlipoproteinparticlesize
AT otvosjamesd adiponectinandlipoproteinparticlesize
AT flyvbjergallan adiponectinandlipoproteinparticlesize
AT miserezandrer adiponectinandlipoproteinparticlesize
AT frystykjan adiponectinandlipoproteinparticlesize
AT sinnreichronit adiponectinandlipoproteinparticlesize
AT karkjeremyd adiponectinandlipoproteinparticlesize